相关实验视频

Updated: May 5, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

在两个地中海国家的脱发区域当前的诊断和治疗实践:基于调查的研究

Michela Starace^1,2, Francesca Pampaloni^1,2, Elisabeth Lazaridou³

¹Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 1, 40138, Bologna, Italy.

Dermatology and therapy

|April 10, 2024

概括

希腊和意大利的皮肤病学家对诊断和治疗脱发症 (AA) 的方法有所不同,这是一种影响生活质量的疾病. 当前的AA管理实践揭示了护理中的重大差距和不一致性.

科学领域:

皮肤病学皮肤病学
流行病学流行病学
临床实践研究临床实践研究

背景情况:

大发性脱发症 (AA) 影响2%的人口,造成显著的心理社会痛苦和生活质量下降.
现有的AA临床实践指南有限,方法质量低.
由于这些指南缺陷,AA管理对临床医生和患者构成挑战.

研究的目的:

在两个地中海国家的皮肤科医生中调查目前的临床实践.
确定AA的诊断和治疗中的潜在差异和差距.
为 AA.改善的临床指导方针的发展提供信息.

主要方法:

以英语编写50项问卷,并将其翻译成希腊语和意大利语.
该问卷通过电子邮件发送给希腊和意大利的皮肤科医生.
从490名意大利和234名希腊皮肤科医生收集了数据.

主要成果:

对AA的诊断依赖于临床评估和三显镜检查,并很少使用严重程度和生活质量评估工具.
局部类固醇是主要的第一线治疗成人和儿童的不整体AA.
针对特定AA呈现的治疗方法 (例如,眉毛,,慢性病例,儿科) 呈现出相当大的异质性.

结论:

包括诊断和治疗在内的带脱发 (AA) 管理仍然是一个复杂的临床挑战.
对AA治疗的显著差异凸显了对标准化,基于证据的临床指导方针的需求.
需要进一步的研究来解决AA护理中的异质性,并改善患者的治疗结果.

关键词:

脱发的区域是有毛发症.诊断诊断诊断诊断诊断管理管理管理管理治疗方法治疗方法

更多相关视频

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Collecting Hair Samples for Hair Cortisol Analysis in African Americans

Collecting Hair Samples for Hair Cortisol Analysis in African Americans

Published on: June 10, 2018

相关概念视频

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...